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Abstract: Perturbations of the colonic microbiota can contribute to the initiation and progression of
colorectal cancer, leading to an increase in pathogenic bacteria at the expense of protective bacteria.
This can contribute to disease through increasing carcinogenic metabolite/toxin production, inducing
inflammation, and activating oncogenic signaling. To limit disease progression, external factors
that may influence the colonic microbiota need to be considered in patients with colorectal cancer.
One major factor that can influence the colonic microbiota is iron. Iron is an essential micronutrient
that is required by both prokaryotes and eukaryotes for cellular function. Most pathogenic bacteria
have heightened iron acquisition mechanisms and therefore tend to outcompete protective bacteria
for free iron. Colorectal cancer patients often present with anemia due to iron deficiency, and thus
they require iron therapy. Depending upon the route of administration, iron therapy has the potential
to contribute to a procarciongenic microbiota. Orally administered iron is the common treatment
for anemia in these patients but can lead to an increased gut iron concentration. This suggests the
need to reassess the route of iron therapy in these patients. Currently, this has only been assessed in
murine studies, with human trials being necessary to unravel the potential microbial outcomes of
iron therapy.
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1. Introduction
The gut microbiota comprises an intricate population of microorganisms, which exert a complex
relationship with their host during both homeostasis and disease. Numerous gastrointestinal diseases,
including colorectal cancer, are associated with changes in gut microbiota compared to healthy
controls [1]. These perturbations, often referred to as dysbiosis, may have a role in contributing to disease
mechanisms associated with colitis, tumor initiation, and tumor progression [2,3]. This dysregulation
in the gut microbiota is potentially associated with a shift away from strains of bacteria beneficial to
the host (symbionts), which act to limit the development of such diseases, substituting with potentially
pathogenic bacteria (pathobionts) that can contribute to inflammation and carcinogenic metabolite
production [4]. As microbial alterations are pre-existent in colorectal cancer, special care needs to be
considered in order to limit external influences that may further shift microbial populations towards a
procarciongenic microbiota [5]. One critical factor that needs to be considered is iron, as this nutrient is
required by many bacterial cells to grow and survive [6]. Patients with colorectal cancer often present
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with anemia due to iron deficiency and are subsequently treated with iron supplements. If enteral iron
is given, this can contribute to an increased luminal iron pool within the gut [7,8]. Many pathogenic
bacteria have high-affinity iron acquisition mechanisms such as siderophores and transferrin/lactoferrin
receptors to obtain free iron from their environment. Therefore, excessive luminal iron may select for
pathogenic bacteria at the expense of beneficial commensal bacteria [9,10]. The role of increased iron in
promoting pathogenic bacteria has been evaluated in an in vitro study by Kortman et al., who assessed
the growth of prevalent enteric pathogens in high and low iron cultures. Growth of pathogenic bacteria
such as Salmonella typhimurium was increased in response to high iron and showed increased adhesion
and invasion of colorectal cancer cells [11]. This supports the idea that oral iron supplementation can
promote the growth and potentially the virulence of pathogenic bacteria through increasing colonic
iron availability [9,11]. Increased colonic iron concentration through iron supplementation has also
been shown to promote pathogenic bacterial species in iron-deficient Kenyan infants while decreasing
protective bacteria such as Bifidobacteria and lactobacillus. This supports the role of increased luminal
iron promoting pathogenic bacteria at the expense of beneficial bacteria, however, the underlying
mechanisms are not fully understood [12,13]. The relationship between the microbiota and colorectal
cancer will be discussed in this review, focusing on how iron can alter bacterial populations and the
outcomes of iron supplementation.
2. Microbiota in Colonic Homeostasis and Disease
2.1. Gut Microbiota
The human intestine provides a platform for a complex and dynamic ecosystem, consisting of
greater than 1013 microorganisms. This collection of microorganisms residing within the gastrointestinal
tract consists of bacteria, viruses, and fungi and is collectively termed the gut microbiota [14]. The gut
microbiota consists of over 400 bacterial species that colonize the lumen and mucosa of the colon but do
not penetrate a healthy bowel wall [3]. The predominant phyla residing within the gut are Firmicutes
(≈49–76%), Bacteroidetes (≈16–23%), Proteobacteria (<10%) and Actinobacteria (<5%), with a large
diversity at the lower taxonomic levels [9].
Bacterial colonization of the colon can be either commensal or pathogenic [15]. Commensal
bacteria can either derive benefit from the host, but the host receives no benefit or harm from the
bacteria, or commensal bacteria can provide a mutualistic relationship with the host when both
bacteria and host benefit. This can act to maintain host homeostasis through contributing to fiber
digestion, synthesis of vitamins, and enterohepatic deconjugation of metabolites [16]. These commensal
bacteria also contribute host defense against colonic invasion of pathogens, due to both requiring an
analogous ecological niche. Hence, under normal physiological conditions, the commensal bacteria
act to outcompete potential pathogenic colonization of the colon, therefore preventing infection [17].
The gut microbiota generally have a commensal relationship with their host. Nevertheless, there is
the potential for this relationship to be disrupted through an alteration in the composition of bacteria.
This occurs through an imbalance in bacterial populations through the replacement of non-harmful
commensal bacteria with pathogenic bacteria. These pathogenic bacteria can cause harm to the host
through invading the bowel wall, causing inflammation and inducing carcinogenic signaling and
metabolites [18]. Therefore, these bacteria have the potential to contribute to tumorigenesis in the colon;
however, what remains unclear is whether the presence of these bacteria are the cause or consequence
of colorectal cancer [2]. Many studies, as discussed in this review, support the role of the microbiota
in the development of colorectal cancer. However, tumors themselves have the ability to shape the
composition of the microbiota, with tumor genetic profiles being able to differentially influence the
microbiota [19]. This has been assessed in colorectal tumors in a study by Burns et al., showing that
prevalent loss of function (LoF) mutations in cancer-related genes, including APC, ANKRD36C, CTBP2,
KMT2C, and ZNF71, are correlated with defined bacterial populations. The LoF mutations were linked
with microbial profiles that were associated with cancer pathways, including mitogen-activated protein
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(MAP) kinase and Wnt signaling [20]. This suggests that the tumor has the ability to regulate the
microbiota, through cancer genetics, in order to potentially support tumor progression [19,20].
2.2. Bacteria and Cancer
The correlation between bacterial infection and cancer is predominantly through three mechanisms:
initiating chronic inflammation, producing carcinogenic metabolites and toxins, and activating
oncogenic signaling (Figure 1) [21]. The most prominent association between bacteria and cancer
is Helicobacter pylori and gastric cancer [22]. Helicobacter pylori is a Gram-negative bacterium that
colonizes the lining of the stomach. Here, it may induce chronic gastritis, which can contribute to the
development of gastric ulcers and stomach cancer [23,24]. Helicobacter pylori also produce virulence
factors such as cytotoxin-associated gene A and vacuolating cytotoxin A, which can contribute to the
damage and malignant transformation of the gastric epithelia [25]. It is estimated that Helicobacter
pylori-positive patients have a 10–20% lifetime risk of developing peptic ulcers and a 1–2% risk of
developing gastric cancer [26]. Helicobacter pylori have also been associated with other pathologies
such as colorectal polyps and cancer [27].
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3. Gut Microbiota and Colorectal Cancer
Cancer occurrence in the large intestines is approximately 12-fold higher than the small
intestines [33]. This may be credited to the much greater bacterial density in the large intestines
(≈1012 cells per mL) compared to small intestines (≈102 cells per mL) [34]. Supporting a role of
microbiota and colorectal cancer, mice that are genetically susceptible to colorectal cancer display
a significantly reduced frequency of oncogenic mutations and tumor formation when germ-free,
compared to those in the presence of a conventional microbiota [35]. This suggests that the presence of
colonic bacteria may potentially contribute to the initiation and progression of colorectal cancer [36].
Similarly, common risk factors for the development of colorectal cancer such as inflammatory bowel
disease, obesity, and a diet rich in fat and protein have all been associated with alterations of the
microbiota [2,37]. This implies a change in bacterial populations within the gut of colorectal cancer
patients, which may include an increase in pathogenic cancer-associated bacteria and a loss of protective
anti-cancer bacteria. Supporting this, comparisons of gut microbiota between normal individual
and colorectal cancer patients reveals that the predominant flora in colorectal cancer are pathogenic
bacteria such as Escherichia coli strains harboring polyketide synthase (pks) pathogenicity islands,
enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum [38–40]. On the other hand, beneficial
strains of bacteria such as butyrate-producing species have been shown to be under-represented in
colorectal cancers, which is consistent with a reduced amount butyrate being seen in the stool of
colorectal cancer patients compared to normal individuals [41]. The relationship between bacteria and
colorectal cancer is complex and unclear, with symbionts and pathobionts having conflicting roles in the
pathogenesis of the disease [30]. What is also unclear is defining the role of the bacteria in the stages of
colorectal carcinogenesis, with bacteria involved in the initiation of colorectal cancer being described as
bacterial drivers, which are then gradually outcompeted by opportunistic passenger bacteria that have
a competitive advantage within the defined tumor microenvironment. These passenger bacteria can
either promote or hinder cancer progression, depending on whether pathobionts or symbionts flourish
in the tumor environment. Hence, external factors such as diet and medication have the potential to
influence the tumor microbiota, depending on whether they support symbiont or pathobiont bacterial
growth [34].
3.1. Pathobionts and Colorectal Cancer
The microbiota have the potential to contribute to both the initiation and progression of colorectal
cancer through multiple mechanisms including inducing oncogenic signaling, producing carcinogenic
metabolites and toxins, and modulating colonic inflammation, which is summarized in Figure 1.
Persistent activation of the immune system, as seen in inflammation, can contribute to cancer through
the production of growth factors and cytokines that can facilitate tumor growth, perturb differentiation,
and promote cancer cell survival [42,43].
Species of the Clostridium genus, including Clostridium perfringens, Clostridium hylemonae,
Clostridium sordelli, Clostridium scindens, and Clostridium hiranonis, along with Bacteroides fragilis,
Bacteroides vulgatus and Listeria monocytogenes, have been shown to be involved in a multistep
deconjugation and biotransformation process that synthesizes secondary bile acids from primary bile
acids [44–49]. The usual role of primary bile acids is in lipid digestion and cholesterol metabolism;
however, they are also implemented in host–microbe interactions. Primary bile acids are usually
reabsorbed through the enterohepatic circulation; however, they can also act as substrates in bacterial
biotransformation in the colon into secondary bile acids [50]. The secondary bile acids lithocholic
acid and deoxycholic acid have been associated with colonic polyps and colorectal cancer through
increasing oxidative stress-induced colonic inflammation and activating the oncogenic signaling
pathway Wnt [50–55]. A study by Nagengast et al. supported the role of secondary bile acids in
the initiation of colorectal cancer. They determined that patients with colonic adenomas showed an
increase in deoxycholic acids compared to healthy controls [56].
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Hydrogen sulfide-producing bacteria such as Bilophila wadsworthia, Bacteroides fragilis, Helicobacter pylori,
Clostridium septicum, and Streptococcus bovis have also been implemented in the initiation of colorectal
cancer. Hydrogen sulfide is a genotoxic substance that causes genomic instability through damaging
DNA [57,58]. Similarly, hydrogen sulfide can diffuse into colonocytes and interfere with mitochondrial
function, causing an increase in proliferative signaling through activation of the MAP kinase
pathway [59]. Supporting the role of hydrogen sulfide-producing bacteria in colorectal cancer, a
study compared the microbiota of African Americans with and without colorectal cancer. A greater
abundance of sulfidogenic bacteria in colorectal cancer patients were found when compared to healthy
patients [57].
Microbiota associated with the progression of colorectal cancer includes the presence of the
pathogenic bacteria Fusobacterium nucleatum [60]. Fusobacterium nucleatum adheres to the colonic
epithelium, where it can invade and induce inflammatory and oncogenic signaling pathways
contributing to the growth of colorectal cancer cells. This is induced through Fusobacterium adhesin A
(FadA)-induced activation of β-catenin signaling, with FadA levels in colonic tissue from patients with
adenomas and adenocarcinomas being between 10 to 100 times greater than healthy individuals [61].
This has been shown to contribute to the progression of colorectal cancer, as patients with a high
abundance of Fusobacterium nucleatum tend to have more advanced disease with a poorer prognosis
and shorter survival time [62,63].
Escherichia coli is a commensal bacteria residing within the colon, however, pathogenic strains of
phylogenetic group B2 harbor the pks genomic island that can produce the genotoxin colibactin [64].
Colibactin can induce DNA double-strand breaks and chromosomal aberrations that can contribute
to the development of sporadic colorectal cancer [65]. Colibactin-producing Escherichia coli has been
found in 55–67% of colorectal cancer patients, compared to 20% of control patients [65]. Escherichia coli
harboring pks has been shown to contribute to disease severity in mice predisposed to colorectal
cancer [66], supporting a passenger role for Escherichia coli in colorectal cancer. However, given the
potent genotoxic effects of colibactin and Escherichia coli harboring pks being able to induce colorectal
cancer in animal models, a driver role is also plausible [67].
Enterotoxigenic Bacteroides fragilis is a pathogenic bacterium that produces the enterotoxin
Bacteroides fragilis toxin (bft) and is associated with colorectal cancer initiation and progression [68].
This occurs through modulation of the mucosal immune system and inducing alterations in epithelial
cells, leading to a compromised colonic barrier [57,69]. Enterotoxic Bacteroides fragilis has been
associated with colonic pre-neoplastic lesions and has been suggested to be a potential biomarker for
early detection of colorectal carcinogenesis [70]. In a study by Boleij et al., 72.7% of early-stage colorectal
tumors had a bft gene present, while 100% of late-stage tumors had a bft gene present [68]. This supports
the role of enterotoxigenic Bacteroides fragilis in the progression of colorectal cancer, as late-stage tumors
have more carcinogenic bacterial toxin Along with this, the abundance of enterotoxigenic Bacteroides
fragilis in colorectal mucosa has been shown to be an independent predictor of three-year survival [69,71].
This supports the potential role of enterotoxic Bacteroides fragilis as both a driver and pathogenic
passenger bacterium in colorectal carcinogenesis [34].
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Table 1. Potential mechanisms of symbionts and pathobionts in colorectal cancer pathogenesis.
Phylum Class Order Family Genus Species Symbiont orPathobiont Potential Mechanism
Actinobacteria Actinobacteria
Bifidobacteriales Bifidobacteriaceae Bifidobacterium
Bifidobacterium bifidum Symbiont Produces metabolites that can inhibit colorectalcancer cell growth [72].
Bifidobacterium lactis Symbiont Inhibits NF-κB signaling, limitingcolitis-associated colorectal cancer [73].
Bifidobacterium longum Symbiont
Lactic acid-producing bacteria that inhibits
colorectal tumor cell proliferation through




Binds free iron, reducing iron for pathogenic
bacteria and reactive oxygen species
production [75].
Propionibacteriales Propionibacteriaceae Propionibacterium Propionibacteriumfreudenreichii Symbiont
Exerts a protective effect against colorectal cancer
through the production of short-chain fatty acids,





Degrades E-cadherin and activates beta-catenin
signaling, upregulating c-Myc expression and
contributing to colonic cellular proliferation [77].
Secretes B. fragilis toxin that can induce STAT3
signaling [78].
Bacteroides vulgatus Pathobiont
Involved in the hydrolysis of primary bile acids to
secondary bile acids, which is associated with
colitis and oncogenic signaling [49,79]. Correlated
with systemic inflammation and colorectal cancer
tumor stage [79].
Rikenellaceae Alistipes Alistipes finegoldii Pathobiont
Linked to colitis-associated colorectal cancer;
in vivo studies have shown to be through
activation of IL-6/STAT3 signaling [80].
Firmicutes Bacilli Lactobacillales
Enterococcaceae Enterococcus Enterococcus faecalis Pathobiont
Can produce reactive oxygen and nitrogen species





Can produce conjugated linoleic acids from
linoleic acid. Fatty acids produced by these species
act on colonocytes, possessing antiproliferative
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Table 1. Cont.
Phylum Class Order Family Genus Species Symbiont orPathobiont Potential Mechanism
Firmicutes
Bacilli
Streptococcaceae Streptococcus Streptococcusbovis/gallolyticus Pathobiont
Can induce production of cytokines that lead to
free radical production, colonic inflammation, and
increased angiogenesis. Contributes to
pro-proliferative signaling via MAP kinase and
COX-2/prostaglandin induced cellular
proliferation and inhibited apoptosis [83].
Bacillales Bacillaceae Bacillus Bacillus subtilis Symbiont
Probiotic bacteria that can inhibit the proliferation
of colorectal cancer cells, induces cell cycle arrest,
and promotes apoptosis. Shown to reduce
inflammation and aids in immune
homeostasis [59].
Clostridia Clostridiales
Clostridiaceae Clostridium Clostridium butyricum Symbiont
Produces butyrate, which possesses anticancer
properties, inducing cell differentiation and
apoptosis, as well as inhibiting cellular
proliferation [84,85].
Lachnospiraceae
Eubacterium Eubacterium rectale Symbiont Anti-inflammatory butyrate-producing
bacteria [86].Roseburia Roseburia intestinalis
Peptostreptococcaceae Peptostreptococcus Peptostreptococcusanaerobius Pathobiont
Has been shown to interact with Toll-like
receptors 2 and 4 on colonic cells. Elevating levels
of reactive oxygen species, promoting cell
proliferation and increasing colonic dysplasia [87].
Ruminococcaceae Faecalibacterium Faecalibacteriumprausnitzii Symbiont
Butyrate-producing bacteria, shown to be
anti-inflammatory and able to inhibit colorectal
tumorigenesis [88–90].
Fusobacteria Fusobacteriia Fusobacteriales Fusobacteriaceae Fusobacterium Fusobacteriumnucleatum Pathobiont
FadA medicated activation of beta-catenin can
contribute to inflammatory and oncogenic
signaling [61]. Fap2 protein present on F.
nucleatum binds to TIGIT on the antitumor
immune cells, natural killer cells, and T-cells,
which can limit tumor immunosurveillance [91].
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Table 1. Cont.
Phylum Class Order Family Genus Species Symbiont orPathobiont Potential Mechanism
Proteobacteria







Produces the bacterial genotoxin colibactin that
promotes the growth of colonic tumor cells.
Colibactin induces DNA interstrand crosslinks
and double-strand breaks [93,94].
Salmonella Salmonellatyphimurium Pathobiont
Produces the bacterial protein AvrA, which is
associated with inflammation and colorectal
cancer, through modulation of the p53
pathway [95,96].
Verrucomicrobia Verrucomicrobiae Verrucomicrobiales Akkermansiaceae Akkermansia Akkermansiamuciniphila Pathobiont
A mucin-degrading bacterium that contributes to
colonic inflammation [97].
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3.2. Symbionts and Colorectal Cancer
In contrast, other bacterial populations can have a protective effect against colorectal cancer.
For instance, Bifidobacterium thermophilum binds free iron to its surface, reducing iron for pathogenic
bacterial growth and reducing free radical formation, both of which can contribute to cancer
progression [75]. Likewise, Lactobacillus acidophilus and Bifidobacterium longum have been seen to
have a protective effect against cancer, forming a barrier against colonization by pathogenic bacteria
and inactivating carcinogenic compounds [98,99].
Gut bacterial populations such as Bifidobacterium and Firmicutes produce the short-chain fatty acid
(SCFA) butyrate, which is believed to possess anti-cancerous properties. Butyrate is a key energy source
for colonocytes, maintaining intestinal epithelium integrity and playing a central role in regulating the
stability of the microbiota [100–102]. Within colorectal cancer cells, butyrate is able to inhibit histone
deacetylase, which leads to increased expression of genes involved in inhibiting the cell cycle and
inducing apoptosis [103]. Butyrate can also control cancer through regulating immune homeostasis,
leading to a reduction in pro-inflammatory immune cells and cytokines [104]. As butyrate is able
to have a protective effect against cancer, this explains why patients with colorectal cancer have
significantly reduced abundance of butyrate-producing bacteria compared to healthy patients [100].
Furthermore, murine studies have shown that supplementation with butyrate-producing bacteria and
dietary fiber was associated with a reduction in tumor growth [105,106].
A study by Dai et al. assessed bacterial populations that tend to be upregulated and depleted in
colorectal cancer. They found five protective bacteria that were decreased in colorectal cancer patients
compared to controls. These included Clostridium butyricum, which promotes apoptosis of colorectal
cancer cells and inhibits intestinal tumor development in mice [59]. This supports the depletion of
protective bacterial species that can prevent or limit cancer growth in colorectal cancer, which can
potentially be replaced by pathogenic species that support tumors [107].
4. Dysbiosis and Bacterial Iron Utilization
Environment, lifestyle, and dietary factors all play key roles in regulating the composition
and function of the human microbiota [108]. Hence, these certain factors may alter the microbiota
to potentially support tumorigenesis. Obesity, smoking, alcohol, and red and processed meat
consumption have all been suggested to have a relationship between the microbiota and colorectal
cancer [109]. Smoking has been shown to reduce the abundance of butyrate-producing Bifidobacterium,
which has anti-inflammatory and anti-tumoral properties [110]. Likewise, obesity has been shown
to promote colorectal cancer development through increasing microbial derived pro-inflammatory
molecules, such as lipopolysaccharides, along with microbially induced epigenetic alterations [109,111].
Many dietary components have been shown to contribute to colorectal cancer. Red meat possesses
procarciongenic properties through increasing secondary bile acids and hydrogen sulfide that can
contribute to oxidative stress and cellular proliferation in colorectal cancer. Along with this, dietary
heme iron from red meat has been shown to increase mucin-degrading bacteria, such as Akkermansia
muciniphila, which can lead to an impairment of gut barrier function and contribute to colorectal
disease [109].
Colonic nutrient availability is a key regulator of gut microbial populations and is regulated
through diet [17]. Many dietary nutrients can regulate colonic bacterial populations, with a major
contributor being iron [112]. Iron availability is vital for humans and microbes; hence, both multi-
and unicellular organisms have developed strategies to obtain iron from their proximate environment
through evolutionarily conserved methods [9]. Iron has a universal role required for protein and
enzymatic function, as well as for energy production, and is essential to fundamental biological
processes of cell growth and differentiation [113]. Humans obtain iron from their diet and through iron
recycling within the body. Dietary iron comes in the form of heme iron from red meat and non-heme
iron from dark green leafy vegetables [114,115]. Dependent on iron consumption, around 15% of
dietary iron is absorbed within the duodenum, with the remnant passing into the large intestine where
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it has the potential to be utilized by colonic bacteria. These bacteria are able to produce high-affinity
iron-chelating molecules called siderophores, as well as transferrin/lactoferrin receptors, which allow
bacteria to scavenge for free iron within the colon. Iron is essential for both the survival and replication
of nearly all bacteria [6,9].
A study by Parmanand et al. used an in vitro model to assess the effect of a decrease in gut
iron availability on the microbiota. They found that the growth of potentially pathogenic bacterial
species, such as Salmonella typhimurium and Escherichia coli, was significantly inhibited when cultured
in an iron-deficient medium, whereas probiotic bacterial species such as Lactobacillus rhamnosus were
unaffected by iron depletion [116]. This suggests a role of luminal iron in promoting the growth of
pathogenic bacteria, but not of probiotic bacteria. This has been assessed in anemic African children
who were given iron-fortified biscuits. Iron fortification increased the abundance of pathogenic
enterobacteria while decreasing the abundance of beneficial lactobacilli. This change is also associated
with increased gut inflammation, as shown by a raised fecal calprotectin concentration. This indicates
that increasing dietary iron within this cohort contributes to gut dysbiosis, as well as suggesting that
increasing pathogenic and decreasing beneficial bacterial populations has the potential to contribute to
disease through inducing gut inflammation [117].
Iron regulation of bacterial populations within the gut presents a complex relationship, with iron
having direct and indirect outcomes on bacterial populations. This can be seen in species of the
Bacteroides genus that require both heme and non-heme iron for growth [118]. Bacteroides species present
a prominent proportion of the gut microbiota, with different species showing pathogenic, probiotic, or
both properties. Therefore, increasing iron colonic concentration has the potential to directly influence
both pathogenic and probiotic Bacteroides species [119]. Iron regulation of probiotic Bacteroides species
involved in the metabolism of undigested dietary fiber can also have an indirect influence on potentially
pathogenic strains of Escherichia coli. This is through the production of a nutrient niche from the release
of sialic acid from mucus and undigested carbohydrates. This facilitates Escherichia coli growth as
they do not produce their own sialidase enzyme and are reliant on other residential bacteria [120].
Therefore, an increase in iron availability can have an indirect effect on bacterial populations through
producing a nutrient niche by probiotic bacteria, which can be utilized to facilitate potential pathogenic
bacterial growth, such as Escherichia coli harboring pks genomic islands [11].
5. Iron Supplementation, Microbiota, and Colorectal Cancer
Alterations in the colonic microbiota play a key role in the pathogenesis of colorectal cancer
through an increase in pathogenic bacterial populations at the expense of protective probiotic
species [121]. Many pathogenic bacteria have heightened iron acquisition mechanisms to aid in
their growth and virulence. This can alter microbial populations when there is an increase in gut
luminal iron concentration [122–124]. Along with diet, oral iron supplementation to treat anemia can
also contribute to luminal iron concentration and therefore has the potential to alter colonic bacterial
populations [125]. Patients with colorectal cancer often present with iron deficiency anemia, which is
commonly induced through chronic tumor-induced blood loss, impairment of iron homeostasis through
chronic inflammatory disease, and reduced iron absorption [126]. Anemia in colorectal cancer patients
is associated with postoperative complications and poorer patient outcomes; therefore, iron therapy
is essential in order to correct anemia peri-operatively [126–128]. However, depending upon the
route of administration, iron therapy can lead to an increase in luminal iron available for pathogenic
bacteria [36]. Oral iron is currently the most common treatment for anemia in colorectal cancer
patients, however, along with multiple gastrointestinal side effects such as abdominal pain, dyspepsia,
and diarrhea, oral iron has the potential to increase procarciongenic bacterial populations [129,130].
The contribution of iron supplementation to microbial alterations in colorectal cancer has been
assessed in murine studies. Constante et al. compared the effect of oral iron supplements to systemic
iron supplementation. They found that oral heme iron altered microbial populations, inducing dysbiosis
and specifically decreasing butyrate-producing taxa, which ultimately was associated with a decrease
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in fecal butyrate levels. Thus, oral iron has the potential to worsen disease by reducing butyrate,
which has anti-inflammatory and anti-cancerous properties. This was confirmed by demonstrating that
dietary heme worsened colitis with greater development of adenoma formation in the mouse model
compared to systemic iron [131]. This suggests that the use of intravenous iron supplementation could
be more beneficial than oral iron, potentially reducing microbial changes, inflammation, and colorectal
cancer progression. These murine studies require detailed exploration with a view to translation into
human clinical trials in order to confirm the microbial implications of oral iron therapy before this can
lead to a change in the clinical administration of iron to treat anemia in colorectal cancer.
Patients with inflammatory bowel disease are at a higher risk of developing colorectal cancer
compared to the general population. Similar to colorectal cancer, the pathology of inflammatory
bowel disease involves alterations in the microbiota and is also associated with anemia, with patients
requiring iron therapy [132,133]. Human clinical studies investigating oral iron against intravenous
iron therapy on the intestinal microbiota in patients with inflammatory bowel disease have been
conducted by Lee et al. They found that oral iron differentially altered both bacterial phylotypes and
fecal metabolites compared to intravenous iron therapy notably leading to a decreased Faecalibacterium
prausnitzii and Ruminococcus bromi abundance following oral iron therapy [122]. Faecalibacterium
prausnitzii is an abundant bacteria in a healthy gut microbiota that possesses anti-inflammatory
properties through producing butyrate [134,135]. Likewise, Ruminococcus bromi is involved in butyrate
production through degrading resistant starch particles [136]. A decreased abundance of these bacteria
in inflammatory bowel disease patients can, therefore, contribute to the pathogenesis of disease through
contributing to inflammation [137]. As inflammatory bowel disease can be a premalignant condition,
the microbial mechanisms underpinning the pathology of the condition may have a similarity to
those in colorectal cancer [132]. Hence, the negative impact of oral iron therapy on the microbiota in
inflammatory bowel disease may act as an indicator of the potential outcomes in colorectal cancer.
However, as colorectal cancer can develop from a non-inflammatory bowel disease origin and because
the microbial mechanisms are not identical, clinical studies investigating this phenomenon in colorectal
cancer are required to fully unravel the potential adverse outcomes of oral iron therapy [138].
6. Molecular Pathological Epidemiology in Colorectal Cancer
Along with iron, many other nutritional factors are associated with colorectal cancer, with studies on
iron and microbiota having the potential to be confounded by other dietary components. This suggests
the need for widescale studies to investigate the interrelationships between environmental exposure
such as diet and nutrition, microbiota, and genetics. These factors can be addressed in relation
to microbial pathologies and clinical outcomes in colorectal cancer through molecular pathological
epidemiology (MPE) [139]. Modifications of the microbiota may not only be a cause of neoplasia but
may act as an informative biomarker. Hence, MPE can be utilized to identify probable biomarkers to
indicate the potential outcomes of nutritional exposures, such as dietary patterns and medications,
on disease outcomes. Along with this, unraveling the complex interplay between diet, microbe, and host
may provide the potential for therapeutic intervention through dietary alteration and probiotic bacterial
supplementation [140].
Initial MPE studies have investigated the complex relationships between diet, microbiota,
and colorectal cancer, assessing potentially pathogenic bacteria such as Fusobacterium nucleatum,
Escherichia coli, and Bacteroides fragilis and probiotic bacteria genera such as Bifidobacterium and
Lactobacillus. A prudent diet pattern rich in fish, poultry, fruit, vegetables, and whole grains has been
shown to be associated with a lower risk for Fusobacterium nucleatum-positive colorectal cancer, but not
Fusobacterium nucleatum-negative cancer [141], whereas an inflammatory dietary pattern rich in red and
processed meat, sugar, and refined grains is linked with a higher risk of Fusobacterium nucleatum-positive
colorectal cancers, but not with a risk in Fusobacterium nucleatum-negative cancers [142], suggesting that
a prudent diet can decrease the risk of colorectal cancer, as well as the fact that nutritional status can
regulate the microbiota in order to support colorectal cancer [140]. Likewise, long-term consumption
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of a diet rich in red meat and fats have been shown to increase the proportion of Bacteroides fragilis and
Escherichia coli within the gut microbiota. An increase in these potentially pathogenic bacteria in response
to red meat and high-fat diet leads to an increased risk of colorectal cancer, through contributing to
barrier dysfunction, inducing inflammation, and promoting carcinogenic pathways [143]. A study
by Kellingray et al. assessed the outcomes of diet on the abundance of sulfate-reducing bacteria.
They found that a diet rich in Brassica vegetables, such as cabbages, kale, and cauliflower, was associated
with a reduction in hydrogen sulfide-producing bacteria. The authors suggest that a diet rich in Brassica
vegetables can potentially be beneficial to gastrointestinal health through limiting the production of
hydrogen sulfide, which can contribute to a reduction in the incidence and progression of cancer [144].
Bifidobacterium and Lactobacillus are both probiotic genera of bacteria that possess anti-cancer properties
through the production of SCFAs. Both genera of bacteria are increased in response to a high-fiber
diet and can act to reduce inflammation and lower the risk of colorectal cancer [143,145]. As these
bacteria have potential anti-cancer properties, they have been suggested as a potential probiotic therapy
following surgery for colorectal cancer. This has been assessed in a study by Zaharuddin et al., which
involved a probiotic consisting of six viable Bifidobacterium and Lactobacillus bacteria given orally twice
daily for 6 months. The probiotics were able to modify the intestinal microbiota, leading to a reduction
in systemic proinflammatory cytokines following treatment [146]. Future MPE research in the context
of nutrition and microbiota is required to investigate the potential outcomes of iron, both dietary and
supplementary, on bacterial populations in colorectal cancer, and the potential this has to alter clinical
outcomes in these patients.
7. Conclusions
The bacteria that make up a healthy colonic microbiota act to maintain homeostasis and should
elicit a tolerogenic response. However, dysbiosis can cause an increase in pathogenic bacteria at
the expense of protective bacteria, which can contribute to both colitis and cancer. Pathobionts can
contribute to disease through compromising the intestinal wall integrity, inducing inflammation,
contributing to oncogenic signaling, and producing carcinogenic products such as hydrogen sulfide,
secondary bile acids, and bacterial toxins, whereas symbionts can limit inflammation and inhibit tumor
cell growth through the production of butyrate, inactivating carcinogenic compounds, and binding
free iron to their surface to limit pathogenic bacterial growth. Nearly all bacteria require iron for
growth and survival, however, many pathogenic bacteria have highly specialized iron-acquiring
mechanisms that aid in their virulence. This has been supported in studies showing that higher luminal
iron concentration leads to a greater abundance of pathogenic bacteria, while a decrease in gut iron
hinders pathogenic bacterial growth and favors protective bacterial species. As colonic luminal iron
concentration may induce alterations in the composition of the microbiota, any factor that will influence
iron intake needs to be controlled in patients with pre-existing dysbiosis, such as in patients with
colorectal cancer. As patients with colorectal cancer often present with iron deficiency anemia, it may
be more prudent to replenish iron stores parenterally rather than enterally so as to not contribute to the
luminal iron concentration available for pathogenic bacteria. As the passenger bacterial population
in colorectal cancer can either be protective or pathogenic, increased iron availability may support
the induction of pathogenic bacteria that may support tumor progression over protective passenger
bacteria that may hinder disease progression. This has been supported in murine studies showing that
oral iron induces colonic microbial dysbiosis and exacerbates intestinal disease. For this to be translated
into the clinical context, clinical trials investigating iron therapy on microbial populations in colorectal
cancer patients are required, as the potential microbial outcomes and disease progression associated
with iron supplementation may lead to an alteration in the administration route of iron therapy.
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